Effectiveness of Splinting After Collagenase Injection
Status:
Enrolling by invitation
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
Dupuytren disease is a fibroproliferative condition of the palmar and digital fascia. A
collagen containing cord forms which can lead to fixed flexion contracture of one or more
fingers. While there is no cure, many treatment options are available to manage symptoms. One
of these options is injectable collagenase clostridium histolyticum (CCH). CCH is a
combination of two highly selective microbial collagenases that can disrupt collagen types I
and III usually found in cords. Current standard of care after receiving a CCH injection is
daily hand exercises and use of a static night brace for four months. However, there is
limited evidence that use of a night splint after CCH injection has any benefit
post-treatment. The goal of our randomized, controlled trial, is to determine the clinical
effectiveness of splinting after CCH injection. Study subjects will be adults 18 years of age
or older with Dupuytren disease and contracture of one or more digits. Treatment includes
collagenase clostridium histolyticum injection for Dupuytren flexion contraction, with
randomization to static night splint or no splint.